By Sabela Ojea
Predictive Oncology has signed a deal to be taken over by Renovaro in exchange for a newly created series of preferred stock in the biotechnology company.
The AI-driven drug-discovery company on Monday said that the acquisition, which follows a formal review of strategic alternatives put in place since mid-November, would reduce its operating expenses by more than 30% on a combined basis in the near term.
The acquisition is subject to a minimum fundraising of $15 million by Renovaro, as well as formal approval by Predictive Oncology's shareholders.
There is no assurance that an agreement or transaction with Renovaro will be executed.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 06, 2025 09:22 ET (14:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。